A股異動 | 振東製藥(300158.SZ)漲停 醫美題材廣受關注 終止剝離安特製藥
格隆匯6月2日丨振東製藥(300158.SZ)競價一字漲停,封單超50萬手。報6.85元創逾8個月新高價,總市值逾70億元。振東製藥1日公吿,終止資產置換暨關聯交易,振東製藥原擬剝離長期虧損資產安特製藥。振東製藥表示,安特製藥旗下治療脱髮的達霏欣米諾地爾搽劑前幾年銷售差,今年,男性醫美和脱髮經濟等醫美題材受到廣泛關注,達霏欣米諾地爾的銷售增速很快,2021年第一季度的銷售額達5000萬元,第二季度預估也會有很大的增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.